Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEXO.L Regulatory News (EXO)

  • There is currently no data for EXO

Acquisition

11 Apr 2017 15:30

RNS Number : 2115C
Exova Group PLC
11 April 2017
Β 

Β 

STOCK EXCHANGE RELEASE

Β 

11 April 2017

Exova Group plc

Β 

Exova acquires SL Pharma Labs Incorporated

Β 

Exova Group plc ("Exova") EXO.L, the global testing, calibration and advisory services provider, has acquired SL Pharma Labs Incorporated (SL Pharma), a Delaware, US, based business that provides laboratory and clinical manufacture testing services to pharmaceutical, biotechnology and medical device companies.

Founded in 1997, SL Pharma has built a strong reputation in the provision of high value and high quality pharmaceutical product development and testing services focused primarily on the development and clinical manufacture of parenteral, ophthalmic, intranasal and topical drug products. The business has a team of 14 specialists and achieved revenues of around $2.5m in 2016.

Ian El-Mokadem, Chief Executive Officer at Exova, said: "This acquisition complements our existing operations by enhancing Exova's technical expertise in pharmaceutical services and offers a great foundation for further growth in North America. SL Pharma's addition to our portfolio clearly demonstrates our commitment to providing more technically demanding services and developing our capabilities in new markets."

Β 

ENDS

Β 

Β 

Enquiries:

Β 

Andy Jones

Powerscourt

T: +44 (0) 20 7549 0747

E: andy.jones@exova.com

Β 

Andrew Pickup

Corporate Affairs Director, Exova Group plc

T: +44 (0) 7920 243 393

E: andrew.pickup@exova.com

Exova

Β 

Exova is one of the world's leading laboratory-based testing groups, trusted by organisations to test and advise on the safety, quality and performance of their products and operations. Headquartered in Edinburgh, UK, Exova operates 135 laboratories and offices in 33 countries and employs around 4,200 people throughout Europe, the Americas, the Middle East, Asia/Asia Pacific and Africa.

Exova's capabilities help to extend asset life, bring predictability to applications, and shorten the time to market for customers' products, processes and materials. With over 90 years' experience, Exova specialises in testing across a number of key sectors ranging from Aerospace to Fire & Building Products; Oil & Gas and Industrials; Infrastructure & Environment; Transportation; and Health Sciences.

Exova Group plc is registered in England (registration number 08907086). Its legal entity identifier ('LEI') number is 213800BFE317FGSYMZ19.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ACQBBGDSSGBBGRB
Date   Source Headline
24th May 20173:11 pmRNSDirector/PDMR Shareholding
24th May 20171:40 pmRNSResult of AGM
24th May 20171:32 pmRNSAGM Statement
24th May 201712:34 pmRNSForm 8.5 (EPT/RI) - Amendment
24th May 201712:02 pmRNSForm 8.5 (EPT/NON-RI) - Exova Group Plc
24th May 201712:00 pmRNSForm 8.5 (EPT/RI) - Exova Group Plc
24th May 201711:08 amRNSForm 8.3 - Exova Group PLC
24th May 201710:57 amRNSDirector Declaration
24th May 201710:32 amRNSForm 8.5 (EPT/RI)
24th May 201710:13 amRNSForm 8.5 (EPT/RI)
24th May 20179:45 amRNSForm 8.3 - EXOVA GROUP PLC
24th May 20177:00 amRNSTrading Statement
23rd May 201712:20 pmRNSForm 8.5 (EPT/RI) - Exova Group Plc
23rd May 201711:57 amRNSForm 8.3 - Exova Group Plc
23rd May 201710:35 amRNSForm 8.5 (EPT/RI)
22nd May 20173:30 pmRNSForm 8.3 - EXO LN
22nd May 20173:18 pmRNSForm 8.3 - Exova Group Plc
22nd May 201711:52 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
22nd May 201710:34 amRNSForm 8.5 (EPT/RI)
19th May 20172:53 pmBUSForm 8.3 - Exova Group Plc
19th May 20172:03 pmRNSForm 8.3 - [Exova Group Plc]
19th May 20171:57 pmRNSForm 8.3 - Exova Group Plc
19th May 20171:11 pmRNSForm 8.5 (EPT/RI)
19th May 20171:03 pmRNSForm 8.3 - EXOVA GROUP PLC
19th May 201711:35 amRNSForm 8.5 (EPT/RI) Exova Group Plc
19th May 201711:26 amRNSForm 8.5 (EPT/RI)
18th May 201712:22 pmRNSForm 8.3 - Exova Group Plc
18th May 201711:53 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
18th May 201711:52 amRNSForm 8.5 (EPT/NON-RI) - Exova Group Plc
18th May 201711:19 amRNSForm 8.5 (EPT/RI)
18th May 201711:12 amRNSForm 8.3 - Exova Group PLC
18th May 201710:50 amRNSForm 8.5 (EPT/RI)
18th May 20178:30 amRNSAcquisition
17th May 20174:52 pmRNSForm 8.5 (EPT/RI) - Amendment
17th May 20172:56 pmRNSForm 8.3 - Exova Group Plc
17th May 20172:25 pmBUSForm 8.3 - Exova Group Plc
16th May 20172:54 pmBUSForm 8.3 - Exova Group Plc
16th May 201711:52 amRNSForm 8.5 (EPT/RI)
16th May 201711:49 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
16th May 201710:26 amRNSForm 8.3 - EXOVA GROUP PLC
16th May 201710:25 amRNSForm 8.5 (EPT/RI)
15th May 20173:30 pmRNSForm 8.3 - EXO LN
15th May 201711:54 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
15th May 201711:44 amRNSForm 8.3 - Exova Group PLC
15th May 201711:13 amRNSForm 8.5 (EPT/RI)
15th May 201710:41 amRNSForm 8.5 (EPT/RI)
15th May 20179:44 amRNSForm 8.3 - EXOVA GROUP PLC
15th May 20179:39 amRNSDeadline for clarification by Jacobs and PAI
12th May 20173:43 pmRNSRECOMMENDED ACQUISITION OF EXOVA REGULATORY UPDATE
12th May 201711:29 amRNSForm 8.5 (EPT/RI) - Exova Group Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.